uniQure N.V. (QURE)
After hours:
| Previous close | 19.54 |
| Open | 19.74 |
| Bid | 18.50 x 800 |
| Ask | 19.38 x 1000 |
| Day's range | 18.18 - 19.95 |
| 52-week range | 12.52 - 38.80 |
| Volume | |
| Avg. volume | 648,185 |
| Market cap | 891.436M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | 2.77 |
| EPS (TTM) | 6.89 |
| Earnings date | 25 July 2022 - 29 July 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.35 |
- Zacks
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.
- GlobeNewswire
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Bar Chart Bar Chart ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort a
- GlobeNewswire
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows: uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 22 employees as a material inducement to commencing
